Novel Anti-Infective Agents that Act by Enhancing the Host Innate Response

通过增强宿主先天反应发挥作用的新型抗感染药物

• 批准号: nhmrc : 1099428
• 负责人: Prof Philip Thompson
• 金额: $ 44.93万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-anti-infective-innate-response/662452
• 关键词: Novel; Anti; Infective; Agents; Act

Antibiotic resistance is one of our major challenges, with fears expressed that we may soon run out of effective antibiotics for the treatment of infections. The goal of this project is to develop a novel class of antibiotics that acts by enhancing our immune response to infection rather than attacking the bacteria themselves, and therefore will not be susceptible to the development of bacterial resistance. These agents inhibit the degradation of a key enzyme involved in combating infections.

抗生素耐药性是我们面临的主要挑战之一，人们担心我们可能很快就会用完治疗感染的有效抗生素。该项目的目标是开发一种新型抗生素，通过增强我们对感染的免疫反应而不是攻击细菌本身来发挥作用，因此不易产生细菌耐药性。这些药剂抑制参与对抗感染的关键酶的降解。